Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231 patients (116 countries), 3127 patients (2.2%) had a pre-operative SARS-CoV-2 diagnosis. Adjusted 30-day mortality in patients without SARS-CoV-2 infection was 1.5% (95%CI 1.4-1.5). In patients with a pre-operative SARS-CoV-2 diagnosis, mortality was increased in patients having surgery within 0-2 weeks, 3-4 weeks and 5-6 weeks of the diagnosis (odds ratio (95%CI) 4.1 (3.3-4.8), 3.9 (2.6-5.1) and 3.6 (2.0-5.2), respectively). Surgery performed ≥ 7 weeks after SARS-CoV-2 diagnosis was associated with a similar mortality risk to baseline (odds ratio (95%CI) 1.5 (0.9-2.1)). After a ≥ 7 week delay in undertaking surgery following SARS-CoV-2 infection, patients with ongoing symptoms had a higher mortality than patients whose symptoms had resolved or who had been asymptomatic (6.0% (95%CI 3.2-8.7) vs. 2.4% (95%CI 1.4-3.4) vs. 1.3% (95%CI 0.6-2.0), respectively). Where possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. Patients with ongoing symptoms ≥ 7 weeks from diagnosis may benefit from further delay.

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 days of surgery. SARS-CoV-2 diagnosis was defined as peri-operative (7 days before to 30 days after surgery); recent (1-6 weeks before surgery); previous (≥7 weeks before surgery); or none. Information on prophylaxis regimens or pre-operative anti-coagulation for baseline comorbidities was not available. Postoperative venous thromboembolism rate was 0.5% (666/123,591) in patients without SARS-CoV-2; 2.2% (50/2317) in patients with peri-operative SARS-CoV-2; 1.6% (15/953) in patients with recent SARS-CoV-2; and 1.0% (11/1148) in patients with previous SARS-CoV-2. After adjustment for confounding factors, patients with peri-operative (adjusted odds ratio 1.5 (95%CI 1.1-2.0)) and recent SARS-CoV-2 (1.9 (95%CI 1.2-3.3)) remained at higher risk of venous thromboembolism, with a borderline finding in previous SARS-CoV-2 (1.7 (95%CI 0.9-3.0)). Overall, venous thromboembolism was independently associated with 30-day mortality ). In patients with SARS-CoV-2, mortality without venous thromboembolism was 7.4% (319/4342) and with venous thromboembolism was 40.8% (31/76). Patients undergoing surgery with peri-operative or recent SARS-CoV-2 appear to be at increased risk of postoperative venous thromboembolism compared with patients with no history of SARS-CoV-2 infection. Optimal venous thromboembolism prophylaxis and treatment are unknown in this cohort of patients, and these data should be interpreted accordingly.

No abstract

Purpose:To evaluate the accuracy of four MR sequences used as part of a whole-body MRI protocol to detect pulmonary lesions in cancer patients. Materials and Methods:A total of 31 oncology patients were imaged in a 1.5T MR scanner (Magnetom Avanto; Siemens Medical Solutions, Germany) for whole-body staging. MR chest imaging included: axial and coronal T2-weighted (T2w)-short-tau inversion-recovery (STIR), axial T2w turbo spin-echo (TSE), and contrast-enhanced (CE) three-dimensional (3D) volumetric interpolated breathhold examination (VIBE). Multidetector computed tomography (MDCT) of the thorax served as the reference standard. The MDCT and MR images were evaluated independently by two radiologists. Comparative analysis was performed per lesion, per lobe, and per patient. Sensitivity, specificity, and predictive values were determined.Results: Compared to MDCT that detected 268 pulmonary lesions ranging from 2 to 75 mm in diameter, the MR sensitivities were 91.1%, 92.5%, 90.8%, and 87.3% for the coronal STIR, the axial STIR, the axial T2w-TSE, and the axial CE 3D-VIBE, respectively. Undetected pulmonary lesions were either calcified or smaller than 10 mm in the axial diameter. With coronal STIR, six false-positive findings were detected; with axial STIR, 14 were detected; with axial T2w-TSE, 10 were detected; and with 3D-VIBE, seven were detected. Conclusion:Pulmonary MRI is feasible as part of a wholebody MRI protocol. In our study, STIR images achieved high accuracy compared to chest MDCT for pulmonary lesions of 3 mm in size or larger. IN MALIGNANT DISEASES, therapeutic options as well as the patient prognosis strongly depend on the tumor stage. Following recent developments in MR hardware, such as faster MR gradients, moving table technology, and multielement coil designs, MRI of the entire body in a single session is being increasingly utilized as an attractive alternative to computed tomography (CT) for whole-body tumor staging without exposing the patients to radiation (1,2). Due to its high soft-tissue contrast, the diagnostic accuracy of MRI is recognized in the musculoskeletal system, the head, the neck, and the abdomen (2-5). In the thorax, MRI has been used to assess tumors invading the chest wall and for mediastinal and cardiac tumors (6,7). For pulmonary imaging, MR is still perceived as inferior to multidetector CT (MDCT). However, as pulmonary lesion detection is an integral part of whole-body cancer imaging studies, a limited diagnostic accuracy in pulmonary staging could severely hamper the value of whole-body MRI of cancer patients.Recent MRI studies reported encouraging results for the detection of pulmonary nodules larger than 5-8 mm in diameter using single fast breathhold (BH) MR sequences in a limited number of patients (4,5,8 -11). Schroeder et al (11), for example, compared the diagnostic performance of a combined set of axial and coronal half-Fourier acquisition single-shot turbo spin-echo (HASTE) sequences with MDCT in a series of 30 patients and found a sensitivity for the detection ...